To avoid the PD-L1 antibody recognition limit, Zhou et al. presented a new approach for a PD-L1 blockade strategy based on a molecularly imprinted nanostructure called “NanoNiche” to improve T-cell-mediated tumor-killing activity [176]. Here, CD274 is linked to neoplasm.